Back to top
more

Neuronetics (STIM)

(Delayed Data from NSDQ)

$0.78 USD

0.78
58,949

0.00 (0.00%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $0.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Harshit Gupta headshot

Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments

Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of -22.22% and 12.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 9.09% and 0.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates

Integra (IART) delivered earnings and revenue surprises of 1.61% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 26.92% and 2.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates

The Cooper Companies (COO) delivered earnings and revenue surprises of 7.59% and 1.80%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?

Neuronetics (STIM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 34.48% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers

Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.

LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure

Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.

Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan

Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.

Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes

Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.

Bruker's (BRKR) Latest Workflows to Aid Applied Markets

Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.

Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes

Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.